 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| . |  |
. |
VaxGen Smallpox Vaccine Promising In Mice
UPI Senior Medical Correspondent Washington (UPI) Sep 02, 2005 VaxGen said Friday a new study by Japanese researchers suggested its smallpox vaccine might offer 100-percent protection from the deadly viral illness after only a single shot. The U.S. government, since the terrorist attacks on Sept. 11, 2001, and the anthrax letters delivered shortly afterwards, has been rushing to develop a safer smallpox vaccine to help prepare for the threat of an intentional release of the deadly virus. The only currently licensed smallpox vaccine in the United States - DryVax, made by Wyeth in Marietta, Pa. - can have life-threatening side effects. In the study, which appears in the September issue of the Journal of Virology, researchers at the National Institute of Infectious Diseases and the National Cancer Center Research Institute in Japan inoculated mice with VaxGen's candidate vaccine LC16m8, which is a modified strain of the vaccinia virus that is intended to have fewer side effects than DryVax. The results indicated a single shot of the vaccine completely protects mice from vaccinia, said VaxGen, based in Brisbane, Calif. The researchers also compared LC16m8 to the Lister strain of vaccinia, which was used in smallpox vaccines that successfully eradicated the disease worldwide. The strains are very similar on a genetic level, leading the researchers to speculate that LC16m8 would be as effective in protecting against smallpox, VaxGen said. Smallpox kills about 30 percent of those it infects, and it can also leave severe, disfiguring scars, according to the Centers for Disease Control and Prevention. The National Institutes of Health has funded studies of another smallpox vaccine called modified vaccinia virus Ankara or MVA. This vaccine is manufactured by Therion Biologics of Cambridge, Mass., and also contains a weakened or attenuated strain of vaccinia virus with the aim of reducing the potential for life-threatening side effects. Dr. Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Diseases, testified before Congress in July that MVA looked promising in animals and early clinical trials in people. Fauci told United Press International MVA is moving its way toward being a candidate for Project Bioshield, but the government has not yet signed a contract to acquisition supplies of the vaccine. Fauci said LC16m8 is analogous to MVA in the sense that attenuated smallpox vaccines seem to be safe. "The thing we haven't been able to demonstrate conclusively is whether (the attenuated vaccines) are effective" in protecting people from contracting smallpox, he said. The current study with mice that received LC16m8 and were protected from a challenge with vaccinia virus is a good indication that these vaccines will be protective in people, but the Food and Drug Administration may require further studies before granting approval, he said. VaxGen is developing LC16m8 in the United States. The vaccine, which is manufactured by the Chemo-Sero-Therapeutic Research Institute in Kumamoto, Japan, is in Japan's emergency stockpile and has been studied in 50,000 Japanese children. VaxGen spokesman Paul Laland told UPI the company has just completed a phase I/II trial of LC16m8 involving 163 healthy volunteers, and so far the vaccine seems to have an acceptable safety profile. The results of the trial have not yet been released, but Laland said the company plans to present it at a scientific meeting sometime this year. All rights reserved. � 2005 United Press International. Sections of the information displayed on this page (dispatches, photographs, logos) are protected by intellectual property rights owned by United Press International.. As a consequence, you may not copy, reproduce, modify, transmit, publish, display or in any way commercially exploit any of the content of this section without the prior written consent of United Press International. Related Links SpaceWar Search SpaceWar Subscribe To SpaceWar Express 
Millions Face Chemical Plant Terror Risk
Washington (UPI) Aug 31, 2005The former counter-terror chief for Presidents Bill Clinton and George W. Bush is warning that most U.S. infrastructure is still almost as vulnerable as it was on Sept. 11, 2001. And he singled out chemical plants as tempting targets for terrorists seeking to create man-made Bhopal-scale disasters in the United States.
|
|
| |||||||||
| The content herein, unless otherwise known to be public domain, are Copyright 1995-2016 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement All images and articles appearing on Space Media Network have been edited or digitally altered in some way. Any requests to remove copyright material will be acted upon in a timely and appropriate manner. Any attempt to extort money from Space Media Network will be ignored and reported to Australian Law Enforcement Agencies as a potential case of financial fraud involving the use of a telephonic carriage device or postal service. |
